María J. Gutiérrez

Author

María J. Gutiérrez

Also Known As

M GUTIERREZ, M Gutierrez, M. Gutierrez, M. J. Gutierrez, M.J. Gutierrez, Maria Gutierrez, Maria J Gutierrez, Maria J. Gutierrez, Maria Jimena Gutierrez, Maria Jose Diaz Gutierrez

149

Publications

3.4K

Citations

H-Index

100

Concepts

All Affiliations

Children's National Johns Hopkins University George Washington University Johns Hopkins Medicine Merck & Co., Inc., Rahway, NJ, USA (United States)

About

María J. Gutiérrez is an author at Children's National specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	22	1.2K
2	Allergy	3	3	114
3	Public Health	2	2	138
4	Natural Sciences	1	1	99
5	Biochemistry	1	1	99

María J. Gutiérrez

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol Evan A. Stein, Scott Mellis, George D. Yancopoulos, New England Journal of Medicine	2012	659
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies Rajesh Krishna, Matt S. Anderson, Arthur Bergman, The Lancet Metabolic SyndromeHypertensionHealthy IndividualsLipid DisorderCardiovascular Disease	2007	276
Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co‐Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus Damayanthi Devineni, Christopher R. Curtin, David Polidori, The Journal of Clinical Pharmacology	2013	211
Progesterone/RANKL Is a Major Regulatory Axis in the Human Breast Tamara Tanos, George Sflomos, Pablo C. Echeverría, Science Translational Medicine	2013	210
Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study Desmond Padhi, Mark Allison, Alan Kivitz, The Journal of Clinical Pharmacology SclerostinImmunologyPharmacotherapySclerostin Antibody RomosozumabSerum Type 1	2013	182
Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus María J. Gutiérrez, Noah L. Rosenberg, Diane MacDougall, Arteriosclerosis Thrombosis and Vascular Biology	2014	168
Perinatal Exposure to Bisphenol A Increases Adult Mammary Gland Progesterone Response and Cell Number Ayyakkannu Ayyanan, Ouahiba Laribi, Sonia Schuepbach‐Mallepell, Molecular Endocrinology Hormonal ContraceptiveReproductive HealthGynecologyFemale Reproductive FunctionMammary Gland Development	2011	121
First‐in‐man safety and pharmacokinetics of synthetic ozonide <scp>OZ439</scp> demonstrates an improved exposure profile relative to other peroxide antimalarials Joerg J. Moehrle, Stephan Duparc, Christoph Siethoff, British Journal of Clinical Pharmacology	2012	115
Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects Rajesh Krishna, AJ Bergman, Bo Jin, Clinical Pharmacology & Therapeutics High-density LipoproteinHealthy SubjectsBiochemistryPharmacological StudyMedicine	2008	99
Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy Subjects Marian Iwamoto, Larissa Wenning, Goutam C. Mistry, Clinical Infectious Diseases Translational MedicineAllergyHealthy SubjectsRaltegravir LevelsNeurovirology	2008	87

Page 1